Datamonitor believes that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression patients, a market with significant sales volume and few viable treatment options. GSK's gepirone ER is likely to be the first pipeline drug to enter the market and exploit this opportunity, with forecast sales of $615m in 2016.

Scope

Analysis of patient potential, unmet needs and clinical trial design in depression Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the market Detailed profiles of key compounds in development for use in depression, with forecasts of drug revenues to 2016 Discussion of GSK's and Sanofi-Aventis' strategies, and insight from key industry opinion leaders

Highlights

Of the novel pipeline drugs in late-stage development for depression, Datamonitor believes gepirone ER has the most revenue potential over the forecast period. This will be the first pipeline drug to enter the market and compete for market share with current third-line therapies, and has the considerable marketing support of GSK. Wyeth's lifecycle management strategy of developing the Effexor reformulation Pristiq, will not successfully maintain revenues for its depression franchise following generic incursion of Effexor XR in 2010. Agomelatine, a melatonin agonist and serotonin receptor ligand, will be a valuable treatment option for mild/moderate MDD patients with prominent sleep disorder co-morbidity or an add-on therapy for more severe MDD sufferers.

Reasons to Purchase

Understand unmet needs in the depression market based on key opinion leader comments Benchmark key late-stage depression compounds against current market leaders Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential